Investors Alert: Pomerantz Law Firm Highlights Rocket Pharmaceuticals Class Action Lawsuit and Key Deadlines
On July 2, 2025, Pomerantz LLP formally announced the initiation of a class action lawsuit against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). This legal action is particularly crucial for investors who have experienced losses related to their investments in the company. If you find yourself in this situation, it is advisable to reach out to Danielle Peyton at the firm via email at [email protected] or through their phone number, 646-581-9980, or toll-free at 888.4-POMLAW, Ext. 7980. Those interested should also provide their mailing address, telephone number, and the number of shares acquired via email to ensure smooth communication.
The core issue at hand pertains to whether Rocket Pharmaceuticals and several of its executives have engaged in fraudulent activities or other illegal business practices. By contacting Pomerantz, you may also secure a position as the Lead Plaintiff in this class if you acquired Rocket securities during the timeframe defined as the Class Period, which is crucial for anyone looking to make a claim against the company. Note that the deadline to do so is August 11, 2025. Further details and a copy of the complaint can be obtained from www.pomerantzlaw.com.
Rocket Pharmaceuticals recently came under scrutiny following a press release that announced an alarming development regarding RP-A501, its investigational gene therapy intended for treating Danon disease. According to the press release, a serious adverse event occurred during the Phase 2 clinical trial; this incident involved complications related to a severe capillary leak syndrome. As a direct response to this unexpected patient outcome, Rocket Pharmaceuticals voluntarily suspended further dosage in the study and notable was the FDA’s subsequent clinical hold on the trial for a more in-depth evaluation of the situation. Unfortunately, the situation escalated as it was revealed that the patient had passed away due to an acute systemic infection after the adverse event was reported.
These developments led to a dramatic decline in Rocket's stock price. On May 27, 2025, the stock plummeted by $3.94 per share, equating to a staggering 62.84% drop, thereby closing at $2.33 per share. Such information is particularly alarming for shareholders and has incited the current class action lawsuit, as investors seek accountability and wish to understand the extent of the company's responsibilities.
Pomerantz LLP, known as one of the premier law firms specializing in corporate, securities, and antitrust class litigation, has been actively involved in prioritizing the rights of those affected by securities fraud. With a legacy that dates back over 85 years, the firm, founded by Abraham L. Pomerantz, has gained recognition for its successful recovery of multi-million dollar damages for class members, making it an essential ally for investors facing such challenges. The firm operates in several major cities, including New York, London, Chicago, Paris, and Tel Aviv, emphasizing its international reach and commitment to protecting investors' rights.
In summary, if you have suffered losses from your investment in Rocket Pharmaceuticals, it is imperative to act swiftly and reach out to Pomerantz LLP to explore your options in joining this significant class action lawsuit. Don't miss the opportunity to reclaim your losses while holding Rocket accountable for their actions and practices throughout this troubling period.
The core issue at hand pertains to whether Rocket Pharmaceuticals and several of its executives have engaged in fraudulent activities or other illegal business practices. By contacting Pomerantz, you may also secure a position as the Lead Plaintiff in this class if you acquired Rocket securities during the timeframe defined as the Class Period, which is crucial for anyone looking to make a claim against the company. Note that the deadline to do so is August 11, 2025. Further details and a copy of the complaint can be obtained from www.pomerantzlaw.com.
Rocket Pharmaceuticals recently came under scrutiny following a press release that announced an alarming development regarding RP-A501, its investigational gene therapy intended for treating Danon disease. According to the press release, a serious adverse event occurred during the Phase 2 clinical trial; this incident involved complications related to a severe capillary leak syndrome. As a direct response to this unexpected patient outcome, Rocket Pharmaceuticals voluntarily suspended further dosage in the study and notable was the FDA’s subsequent clinical hold on the trial for a more in-depth evaluation of the situation. Unfortunately, the situation escalated as it was revealed that the patient had passed away due to an acute systemic infection after the adverse event was reported.
These developments led to a dramatic decline in Rocket's stock price. On May 27, 2025, the stock plummeted by $3.94 per share, equating to a staggering 62.84% drop, thereby closing at $2.33 per share. Such information is particularly alarming for shareholders and has incited the current class action lawsuit, as investors seek accountability and wish to understand the extent of the company's responsibilities.
Pomerantz LLP, known as one of the premier law firms specializing in corporate, securities, and antitrust class litigation, has been actively involved in prioritizing the rights of those affected by securities fraud. With a legacy that dates back over 85 years, the firm, founded by Abraham L. Pomerantz, has gained recognition for its successful recovery of multi-million dollar damages for class members, making it an essential ally for investors facing such challenges. The firm operates in several major cities, including New York, London, Chicago, Paris, and Tel Aviv, emphasizing its international reach and commitment to protecting investors' rights.
In summary, if you have suffered losses from your investment in Rocket Pharmaceuticals, it is imperative to act swiftly and reach out to Pomerantz LLP to explore your options in joining this significant class action lawsuit. Don't miss the opportunity to reclaim your losses while holding Rocket accountable for their actions and practices throughout this troubling period.
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.